Regeneron Pharmaceuticals, Inc. (REGN) – What Are Analysts Thinking About This Stock?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been given a consensus recommendation of “Moderate Buy” by the thirty-one brokerages that are presently covering the firm, MarketBeat Ratings reports. Eight research analysts have rated the stock with a hold rating, twenty-two have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $850.83.

A number of equities analysts recently issued reports on the stock. Truist Financial upped their price target on shares of Regeneron Pharmaceuticals from $772.00 to $780.00 and gave the stock a “buy” rating in a research note on Wednesday, October 7th. Citigroup raised their price objective on shares of Regeneron Pharmaceuticals from $740.00 to $825.00 and gave the company a “neutral” rating in a research note on Friday. Morgan Stanley upped their target price on shares of Regeneron Pharmaceuticals from $758.00 to $779.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 7th. Wells Fargo & Company increased their price target on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a report on Friday, July 31st. Finally, BMO Capital Markets raised their price target on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company an “outperform” rating in a research report on Wednesday, September 9th.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q3 earnings and revenue beat expectations: Regeneron reported $5.12 billion in revenue, up 36.3% year over year and well above the approximately $4.56 billion analyst consensus. Non-GAAP EPS was $20.07, compared with estimates near $16.42 and $11.83 a year earlier. REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up
• Positive Sentiment: Strong commercial performance: Sanofi-partnered Dupixent generated robust demand, while U.S. Eylea HD sales increased 62% to $699 million and global Libtayo sales rose 51% to $550 million. The results suggest Regeneron’s product portfolio is offsetting competitive and pricing pressures in older treatments. Regeneron Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: Pipeline and strategic momentum: Regeneron highlighted progress toward upcoming FDA catalysts, expanded its Sanofi collaboration with next-generation long-acting immunology antibodies and received a $1 billion upfront payment to be recognized as collaboration revenue. A new Phase 2 cemiplimab combination study also expands its skin-cancer pipeline. Regeneron Expands Skin Cancer Pipeline With New Cemiplimab Combo Trial
• Neutral Sentiment: Management characterized 2026 as potentially one of Regeneron’s strongest years, and analysts have raised some expectations following the earnings beat. Investors will now focus on whether Dupixent growth and new launches can remain durable.
• Negative Sentiment: Eylea 2 mg remains exposed to biosimilar competition, while at least one analyst recently lowered Regeneron’s price target from $900 to $850. After the sharp upward move, valuation and the need for continued execution could create near-term volatility. Evercore ISI Adjusts Price Target on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Trading Up 13.3%

NASDAQ:REGN opened at $927.89 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The firm has a market capitalization of $95.54 billion, a P/E ratio of 20.49, a PEG ratio of 1.57 and a beta of 0.16. The company’s 50-day simple moving average is $793.30 and its 200 day simple moving average is $738.05. Regeneron Pharmaceuticals has a one year low of $591.52 and a one year high of $935.35.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%. The business had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $4.58 billion. During the same quarter in the previous year, the business earned $11.83 earnings per share. The firm’s quarterly revenue was up 36.3% compared to the same quarter last year. As a group, analysts forecast that Regeneron Pharmaceuticals will post 49.10 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Andrew Murphy sold 4,147 shares of the business’s stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total value of $3,204,386.90. Following the completion of the transaction, the insider owned 47,833 shares in the company, valued at $36,960,559.10. The trade was a 7.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $340,000.00. Following the transaction, the director owned 603 shares in the company, valued at $512,550. This represents a 39.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 8,093 shares of company stock worth $6,506,845 over the last three months. Company insiders own 6.97% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Boston Trust Walden Corp grew its stake in shares of Regeneron Pharmaceuticals by 794.1% in the 3rd quarter. Boston Trust Walden Corp now owns 10,667 shares of the biopharmaceutical company’s stock valued at $8,088,000 after buying an additional 9,474 shares during the period. Chicago Partners Investment Group LLC grew its stake in shares of Regeneron Pharmaceuticals by 29.7% in the third quarter. Chicago Partners Investment Group LLC now owns 2,865 shares of the biopharmaceutical company’s stock worth $2,306,000 after acquiring an additional 656 shares in the last quarter. Covestor Ltd raised its stake in shares of Regeneron Pharmaceuticals by 31.5% in the third quarter. Covestor Ltd now owns 171 shares of the biopharmaceutical company’s stock valued at $130,000 after acquiring an additional 41 shares in the last quarter. Compass Financial Management LLC boosted its holdings in Regeneron Pharmaceuticals by 4,526.2% in the third quarter. Compass Financial Management LLC now owns 3,007 shares of the biopharmaceutical company’s stock valued at $2,280,000 after purchasing an additional 2,942 shares during the period. Finally, Pzena Investment Management LLC acquired a new position in Regeneron Pharmaceuticals during the 3rd quarter worth $310,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.